Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
BMC Psychiatry. 2013 Aug 13;13:211. doi: 10.1186/1471-244X-13-211.
Many new approaches have been adopted for the treatment of bipolar disorder (BD) in the past few years, which strived to produce more positive outcomes. To enhance the quality of care, several guideline recommendations have been developed. For study purposes, we monitored the prescription of psychotropic drugs administered to bipolar patients who had been referred to tertiary care services, and assessed the degree to which treatment met specific guidelines.
Between December 2006 and February 2009, we assessed 113 individuals suffering from BD who had been referred to the Royal Ottawa Mental Health Centre (ROMHC) Mood Disorders Program by physicians within the community, mostly general practitioners. The Structured Clinical Interview for DSM-IV-TR was used to assess diagnosis. The prescribed treatment was compared with specific Canadian guidelines (CANMAT, 2009). Univariate analyses and logistic regression were used to assess the contribution of demographic and clinical factors for concordance of treatment with guidelines.
Thirty-two subjects had BD type I (BD-I), and 81 subjects had BD type II (BD-II). All subjects with BD-I, and 90% of the BD-II group were given at least one psychotropic treatment. Lithium was more often prescribed for subjects with BD-I (62%) than those with BD-II (19%). Antidepressants were the most frequently prescribed class of psychotropics. Sixty-eight percent of subjects received treatment concordant with guidelines by medication and dose. The presence of a current hypomanic episode was independently associated with poorer concordance to guidelines. In more than half the cases, the inappropriate use of antidepressants was at the origin of the non concordance of treatment with respect to guidelines. Absence of psychotropic treatment in bipolar II patients and inadequate dosage of mood stabilizers were the two other main causes of non concordance with guidelines.
The factors related to treatment not concordant with guidelines should be further explored to determine appropriate strategies in implementing the use of guidelines in clinical practice.
在过去的几年中,许多新的方法已被用于治疗双相情感障碍(BD),以取得更积极的结果。为了提高护理质量,已经制定了几项指南建议。出于研究目的,我们监测了转介至三级护理服务的双相情感障碍患者的精神药物处方,并评估了治疗符合特定指南的程度。
在 2006 年 12 月至 2009 年 2 月期间,我们评估了 113 名由社区医生(主要是全科医生)转介至渥太华皇家精神健康中心(ROMHC)情绪障碍计划的双相情感障碍患者。使用 DSM-IV-TR 结构临床访谈来评估诊断。将规定的治疗方法与特定的加拿大指南(CANMAT,2009)进行比较。使用单变量分析和逻辑回归来评估人口统计学和临床因素对治疗与指南一致的贡献。
32 名患者为双相情感障碍 I 型(BD-I),81 名患者为双相情感障碍 II 型(BD-II)。所有 BD-I 患者和 90%的 BD-II 患者均接受了至少一种精神药物治疗。锂在 BD-I 患者中的使用频率(62%)高于 BD-II 患者(19%)。抗抑郁药是最常开的精神药物类别。68%的患者在药物和剂量方面接受了与指南一致的治疗。当前轻躁狂发作的存在与较差的指南一致性独立相关。在一半以上的病例中,抗抑郁药的不当使用是治疗与指南不一致的主要原因。双相 II 型患者没有接受精神药物治疗和情绪稳定剂剂量不足是不符合指南的另外两个主要原因。
应进一步探讨与指南不一致的治疗相关因素,以确定在临床实践中实施指南使用的适当策略。